FINWIRES · TerminalLIVE
FINWIRES

中央銀行の決定が欧州証券取引所の正午の取引を支える

By

-- 木曜正午、欧州株式市場は上昇基調で推移した。トレーダーらはペルシャ湾岸情勢の緊張、決算シーズン、そしてイングランド銀行の金利据え置き決定を注視していた。 欧州市場では食品株が上昇を牽引した一方、銀行株は出遅れた。 投資家はウォール街の先物取引の上昇にも注目したが、アジア市場では概ね下落して取引を終えた。 イングランド銀行は、政策金利を3.75%に据え置くと発表した。これは、欧州中央銀行(ECB)も政策金利を2%に据え置くと予想されている決定を数時間後に控えた動きである。 経済ニュースでは、ユーロ圏の4月の年間インフレ率は前年同月比3%になると予想されており、3月の2.6%から上昇するとユーロスタットが発表した。 ユーロスタットによると、第1四半期の季節調整済み国内総生産(GDP)は、ユーロ圏とEUともに0.1%の緩やかな伸びにとどまった。 欧州主要株価指数であるStoxx Europe 600指数は、取引時間中盤で0.6%上昇した。 Stoxx Europe 600テクノロジー指数は0.5%上昇、Stoxx Europe 600銀行指数は0.7%下落した。 Stoxx Europe 600石油・ガス指数は0.4%上昇、Stoxx Europe 600食品・飲料指数は1.2%上昇した。 欧州REIT指数であるREITEは0.4%上昇した。 各国の主要株価指数では、ドイツのDAX指数は0.7%上昇、ロンドンのFTSE 100指数は1.3%上昇した。パリのCAC 40指数は0.1%下落、スペインのIBEX 35指数は0.1%上昇した。 ドイツ10年国債の利回りは低下し、3.07%付近となった。 北海ブレント原油の期近先物価格は1.1%下落し、1バレル109.19ドルとなった。 ユーロ・ストックス50指数の変動率は1.8%上昇し23.77となった。これは今後30日間の欧州株式市場の変動率が平均を上回ることを示しており、ネガティブなシグナルである。20を上回る数値は市場の不安定化を、20を下回る数値は市場の落ち着きを示唆する。

Related Articles

Research

Research Alert: The Clorox Company Beats Estimates Driven By Household And International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CLX reported Q3 FY 26 net sales of $1.67B, flat Y/Y with organic sales down 1%, while adj. EPS of $1.64 grew 13% and beat consensus by $0.10. Gross margin contracted 140 bps to 43.2% due to elevated manufacturing costs and unfavorable mix, though disciplined expense management supported earnings. Mixed segment performance showed Household and International delivering growth of 3% and 8%, respectively, while Lifestyle declined 9% on lower consumption and inventory adjustments. Management updated FY 26 guidance expecting net sales to decline ~6% with organic sales down ~9%, including a 7.5%-pt ERP headwind. Adj. EPS guidance of $5.45-$5.65 represents a 27%-29% decline, with gross margin expected to contract 250-300 bps from GOJO inventory step-up and elevated energy costs. The April 1 GOJO acquisition expands the health portfolio though near-term integration costs pressure results. We believe the completed $580M digital transformation positions CLX for long-term operational improvements despite macro headwinds.

$CLX
Research

Research Alert: Rivn: Q1 Eps Ahead Of Consensus; 2026 Guidance Unchanged

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Rivian (RIVN) posted Q1 adjusted EPS of -$0.55 vs. -$0.41, ahead of the -$0.60 consensus. Revenue rose 11% to $1.38B ($10M ahead of consensus) on a 20% increase in total vehicle sales to 10,365 units, augmented by a 49% Y/Y increase in software and services revenue to $473M. RIVN's gross margin contracted 800 bps to 8.6%, but was ahead of the 8.4% consensus. The quarter's financial results reflect the company's strategic pivot toward broader market accessibility with the R2, though at the cost of near-term profitability. RIVN maintained prior 2026 guidance for adjusted EBITDA, vehicle deliveries, and capex. The company ended Q1 with cash of $4.8B, down from $6.1B at year-end 2025. Shares are trading 1% higher in after-hours trading. RIVN's Q1 earnings were ahead of expectations, although cash burn remains a key concern, with free cash flow deteriorating, driven by increased operating expenses and working capital consumption. Execution risks remain high given challenging demand facing the broader EV industry.

$RiVN
Research

Research Alert: Rmd Posts Mixed Q3 Fy 26 With Solid Margin Expansion Despite Revenue Miss

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ResMed delivered mixed Q3 FY 26 results with revenue growing 11% to $1.43B, $20M below expectations, while non-GAAP EPS of $2.86 rose 21%, beating consensus by $0.06. Geographic performance showed broad strength with U.S./Canada/Latin America up 9% and Europe/Asia expanding 16%, while masks/accessories outpaced devices with 16% vs 9% growth. The standout highlight was gross margin expansion of 290 bps to 62.2% driven by manufacturing efficiencies and component cost improvements, demonstrating operational excellence in our view. The company continues advancing its digital health strategy with new product launches including the AirTouch F30i mask and plans for a 2027 Indiana distribution center. We expect the recently completed VirtuOx acquisition to strengthen diagnostic capabilities within ResMed's digital health ecosystem across 140+ countries, positioning the company well for continued growth in the expanding sleep and respiratory care market.

$RMD